Journal article
An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin
Abstract
Background: This phase I study was performed to evaluate the safety, tolerability, and efficacy of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin in patients with advanced solid tumours, and to identify the maximum tolerated dose of these agents in combination and the dose for use in subsequent studies. Patients and methods: 14 patients were entered onto 3 dose levels consisting of escalating doses of …
Authors
Hirte H; Stewart D; Goel R; Chouinard E; Huan S; Stafford S; Waterfield B; Matthews S; Lathia C; Schwartz B
Journal
Investigational New Drugs, Vol. 23, No. 5, pp. 437–443
Publisher
Springer Nature
Publication Date
October 2005
DOI
10.1007/s10637-005-2903-3
ISSN
0167-6997